A 32-patient trial showed that INS-19, an experimental drug designed by Insmed to boost white blood cells, demonstrated equivalence with Amgen's Neupogen. Insmed plans to meet with the FDA to talk about a late-stage trial and thinks it is the first U.S. firm to report human-bioequivalence data for a follow-on biologic.

Full Story:

Related Summaries